Amgen has made a play in a hot area of immunology R&D, paying $400 million upfront to claim rights to an OX40-targeting drug from Kyowa Kirin that is ready for phase 3 testing for atopi
The US authorities have reported the first-ever case of an H5 strain of avian influenza without a known occupational exposure to sick or infected animals in the country.